<DOC>
	<DOCNO>NCT02795676</DOCNO>
	<brief_summary>This randomize , double blind , active control study PRX-102 Fabry disease patient impaired renal function . Patients treat least 1 year agalsidase beta stable dose least 6 month screen randomized continue treatment either agalsidase beta dose treatment 1 mg/kg PRX-102 . The identity enzyme blind patient investigator . Patients receive intravenous infusion every two week . Patients randomize 2:1 ratio PRX-102 agalsidase beta . Randomization stratify urinary protein creatinine ratio ( UPCR ) &lt; ≥ 1 g/g spot urine sample .</brief_summary>
	<brief_title>Study Safety Efficacy PRX-102 Compared Agalsidase Beta Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Symptomatic adult Fabry disease patient , age 1860 year 1 . Plasma and/or leucocyte alpha galactosidase activity ( activity assay ) less 30 % mean normal level 2 . One describe characteristic feature Fabry disease : i. neuropathic pain , ii . cornea verticillata , iii . cluster angiokeratoma Screening eGFR CKDEPI equation 40 90 mL/min/1.73 m2 Linear negative slope eGFR base least 3 serum creatinine value approximately 1 year ( range 9 18 month , include value obtain screen visit ) ≥ 2 mL/min/1.73 m2/year Treatment dose 1 mg/kg agalsidase beta per infusion every 2 week least one year least 80 % 13 ( 10.4 ) mg/kg total dose last 6 month . History anaphylaxis Type 1 hypersensitivity reaction agalsidase beta History renal dialysis transplantation History acute kidney injury 12 month prior screen , include specific kidney disease ( e.g. , acute interstitial nephritis , acute glomerular vasculitic renal disease ) ; nonspecific condition ( e.g , ischemia , toxic injury ) ; well extrarenal pathology ( e.g. , prerenal azotemia , acute postrenal obstructive nephropathy ) Angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARB ) therapy initiate dose change 4 week prior screen Urine protein creatinine ratio ( UPCR ) &gt; 0.5 g/g treat ACE inhibitor AR Cardiovascular event ( myocardial infarction , unstable angina ) 6 month period randomization Congestive heart failure NYHA Class IV Cerebrovascular event ( stroke , transient ischemic attack ) 6 month period randomization Known history hypersensitivity Gadolinium contrast agent Presence medical , emotional , behavioral psychological condition , judgment Investigator and/or Medical Director , would interfere patient 's compliance requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glomerular filtration rate</keyword>
	<keyword>Proteinuria</keyword>
</DOC>